171 related articles for article (PubMed ID: 27993717)
1. Mapping transmembrane residues of proteinase activated receptor 2 (PAR
Suen JY; Adams MN; Lim J; Madala PK; Xu W; Cotterell AJ; He Y; Yau MK; Hooper JD; Fairlie DP
Pharmacol Res; 2017 Mar; 117():328-342. PubMed ID: 27993717
[TBL] [Abstract][Full Text] [Related]
2. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110).
Suen JY; Barry GD; Lohman RJ; Halili MA; Cotterell AJ; Le GT; Fairlie DP
Br J Pharmacol; 2012 Mar; 165(5):1413-23. PubMed ID: 21806599
[TBL] [Abstract][Full Text] [Related]
3. Proteinase-activated receptor-2: key role of amino-terminal dipeptide residues of the tethered ligand for receptor activation.
Al-Ani B; Hansen KK; Hollenberg MD
Mol Pharmacol; 2004 Jan; 65(1):149-56. PubMed ID: 14722246
[TBL] [Abstract][Full Text] [Related]
4. Proteinase-activated receptor 2: differential activation of the receptor by tethered ligand and soluble peptide analogs.
Al-Ani B; Wijesuriya SJ; Hollenberg MD
J Pharmacol Exp Ther; 2002 Sep; 302(3):1046-54. PubMed ID: 12183662
[TBL] [Abstract][Full Text] [Related]
5. Novel agonists and antagonists for human protease activated receptor 2.
Barry GD; Suen JY; Le GT; Cotterell A; Reid RC; Fairlie DP
J Med Chem; 2010 Oct; 53(20):7428-40. PubMed ID: 20873792
[TBL] [Abstract][Full Text] [Related]
6. Proteinase activated receptor 2: Role of extracellular loop 2 for ligand-mediated activation.
Al-Ani B; Saifeddine M; Kawabata A; Hollenberg MD
Br J Pharmacol; 1999 Nov; 128(5):1105-13. PubMed ID: 10556949
[TBL] [Abstract][Full Text] [Related]
7. Pathway-selective antagonism of proteinase activated receptor 2.
Suen JY; Cotterell A; Lohman RJ; Lim J; Han A; Yau MK; Liu L; Cooper MA; Vesey DA; Fairlie DP
Br J Pharmacol; 2014 Sep; 171(17):4112-24. PubMed ID: 24821440
[TBL] [Abstract][Full Text] [Related]
8. Three Homology Models of PAR2 Derived from Different Templates: Application to Antagonist Discovery.
Perry SR; Xu W; Wirija A; Lim J; Yau MK; Stoermer MJ; Lucke AJ; Fairlie DP
J Chem Inf Model; 2015 Jun; 55(6):1181-91. PubMed ID: 26000704
[TBL] [Abstract][Full Text] [Related]
9. Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2.
Kanke T; Ishiwata H; Kabeya M; Saka M; Doi T; Hattori Y; Kawabata A; Plevin R
Br J Pharmacol; 2005 May; 145(2):255-63. PubMed ID: 15765104
[TBL] [Abstract][Full Text] [Related]
10. A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists.
Compton SJ; Cairns JA; Palmer KJ; Al-Ani B; Hollenberg MD; Walls AF
J Biol Chem; 2000 Dec; 275(50):39207-12. PubMed ID: 10995771
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist.
Cho NC; Seo SH; Kim D; Shin JS; Ju J; Seong J; Seo SH; Lee I; Lee KT; Kim YK; No KT; Pae AN
J Comput Aided Mol Des; 2016 Aug; 30(8):625-37. PubMed ID: 27600555
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2.
Lieu T; Savage E; Zhao P; Edgington-Mitchell L; Barlow N; Bron R; Poole DP; McLean P; Lohman RJ; Fairlie DP; Bunnett NW
Br J Pharmacol; 2016 Sep; 173(18):2752-65. PubMed ID: 27423137
[TBL] [Abstract][Full Text] [Related]
13. Biased Signaling by Agonists of Protease Activated Receptor 2.
Jiang Y; Yau MK; Kok WM; Lim J; Wu KC; Liu L; Hill TA; Suen JY; Fairlie DP
ACS Chem Biol; 2017 May; 12(5):1217-1226. PubMed ID: 28169521
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2).
Ramachandran R; Mihara K; Chung H; Renaux B; Lau CS; Muruve DA; DeFea KA; Bouvier M; Hollenberg MD
J Biol Chem; 2011 Jul; 286(28):24638-48. PubMed ID: 21576245
[TBL] [Abstract][Full Text] [Related]
15. The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo.
Flynn AN; Tillu DV; Asiedu MN; Hoffman J; Vagner J; Price TJ; Boitano S
J Biol Chem; 2011 May; 286(21):19076-88. PubMed ID: 21467041
[TBL] [Abstract][Full Text] [Related]
16. A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells.
Jiang Y; Yau MK; Lim J; Wu KC; Xu W; Suen JY; Fairlie DP
J Pharmacol Exp Ther; 2018 Feb; 364(2):246-257. PubMed ID: 29263243
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands.
Kawabata A; Saifeddine M; Al-Ani B; Leblond L; Hollenberg MD
J Pharmacol Exp Ther; 1999 Jan; 288(1):358-70. PubMed ID: 9862790
[TBL] [Abstract][Full Text] [Related]
18. Tethered ligand-derived peptides of proteinase-activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells.
Hansen KK; Saifeddine M; Hollenberg MD
Immunology; 2004 Jun; 112(2):183-90. PubMed ID: 15147561
[TBL] [Abstract][Full Text] [Related]
19. Modified proteinase-activated receptor-1 and -2 derived peptides inhibit proteinase-activated receptor-2 activation by trypsin.
Al-Ani B; Saifeddine M; Wijesuriya SJ; Hollenberg MD
J Pharmacol Exp Ther; 2002 Feb; 300(2):702-8. PubMed ID: 11805236
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of protease-activated receptor 2 protects against experimental colitis.
Lohman RJ; Cotterell AJ; Suen J; Liu L; Do AT; Vesey DA; Fairlie DP
J Pharmacol Exp Ther; 2012 Feb; 340(2):256-65. PubMed ID: 22028393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
